Epigenetic modifications in pediatric acute lymphoblastic leukemia

Michael J. Burke1* and Teena Bhatla2

1 Division of Pediatric Hematology-Oncology, Medical College of Wisconsin, Milwaukee, WI, USA
2 Division of Pediatric Hematology-Oncology, New York University Langone Medical Center, New York, NY, USA

INTRODUCTION

Epigenetics is the study of biochemical modifications of chromatin (1) and have been implicated in the pathogenesis of cancer (2). Epigenetic modifications to DNA are not secondary to changes to the nucleotide sequence itself but rather heritable changes affecting the activity of genes and their cellular expression. Examples include DNA methylation, histone modification, and alterations in non-coding microRNAs (miRNAs). Each of these mechanisms can alter how genes are expressed or silenced without modifying the DNA sequence. If these epigenetic modifications lead to silencing of tumor suppressor genes or activation of oncogenes then it is easy to conceptualize how leukemogenesis can occur.

Unlike chromosomal translocations or gene mutations, which are permanent, hypermethylation of gene promoters is a reversible event that could be targeted with therapeutic agents designed to alter aberrant epigenetic events. Incorporating epigenetic modifying agents into the treatment of pediatric ALL is an exciting approach that theoretically could have a significant impact in the treatment of this disease. This would be particularly true for relapse ALL, which is highly hypermethylated (3–5), and accounts for more deaths than any other pediatric disease and remains the fifth most common pediatric cancer overall (6).

In this brief review, we will focus on the three main areas of epigenetics, which have been implicated in the leukemogenesis of pediatric ALL; DNA hypermethylation, histone modification, and microRNA alterations. As we continue to gain better understanding of the driving mechanisms for pediatric ALL at both diagnosis and relapse, therapeutic interventions directed toward these pathways and mechanisms can be harnessed and introduced into clinical trials.

DNA HYPERMETHYLATION

Gains of DNA methylation tend to occur in the gene promoter region and are one of the most studied epigenetic abnormalities in oncogenesis (7, 8). The methylation occurs at cytosine (C) bases located 5′ to guanosine (G) in a CpG dinucleotide and often in regions rich in repetitive CpGs known as CpG islands. The methyl groups are transferred to the CpG dinucleotide via DNA methyltransferases (Dnmt1, Dnmt3a, and Dnmt3b) and serve to transcriptionally silence genes downstream of the methylated promoter. When aberrant methylation occurs in a cancer cell, it typically results in hypermethylation of tumor suppressor genes. This can lead to disruption of key molecular pathways such as apoptosis, DNA repair pathways, cell cycle checkpoints, and cell differentiation as well as result in activation of metastasis/invasion pathways, drug resistance, and proliferation signal transduction (9).

Various groups have used DNA methylation studies to investigate the underlying epigenetic mechanisms in childhood leukemia. In a large cohort of 137 B-lineage and 30 T-lineage pediatric ALL cases, distinct DNA methylation signatures with significant concordant correlation of gene expression were found to be characteristic of various cytogenetic sub-types (10). In fact, a core set of epigenetically deregulated genes, common to all cases, was identified; suggesting their central role in leukemia initiation and maintenance. Likewise, DNA methylation interrogation of 69 pediatric B-ALL and 42 non-leukemic control samples revealed 325 genes hypermethylated and down regulated, and 45 genes hypomethylated and up-regulated across all the samples, irrespective of subtype (11). Furthermore, gene ontology analysis of these epigenetically deregulated genes highlighted the role of genes involved in cell signaling, cellular development, cell survival, and apoptosis. Another study investigating 764 cases of newly diagnosed ALL and 27 cases of relapse, identified 9406 predominantly hypermethylated CpG sites, independent of cytogenetic background, with each cytogenetic subtype displaying a unique set of hyper- and hypomethylated sites (12). These differentially hypermethylated CpG sites were enriched for genes in...
the transcriptional regulatory network such as NANOG, OCT4, SOX2, and REST. These genes are known to be regulated by a polycomb group of proteins and have been identified as targets for hypermethylation in solid tumors (13), leukemia (14), and lymphoma (15).

MLL-rearranged infant leukemia is one specific ALL subtype that has been shown to exhibit distinct promoter hypermethylation (16–19). Stumpel and colleagues identified a distinct DNA methylation pattern dependent on the presence and type of MLL-fusion partner in a cohort of 57 newly diagnosed infant ALL patients (19). In addition, the degree of hypermethylation appeared to correlate with a higher risk of relapse among infants carrying t(4;11) or t(11;19) translocations. In another study of 5 MLL-rearranged infant ALL samples, genes known to be involved in oncogenesis and tumor progression (DAPK1, CCR6, HRK, LIFR, and FHIT) were differentially methylated suggesting a role in the leukemogenesis of MLL-rearranged ALL (17). As well, four of five genes that were hypermethylated and silenced were able to be re-expressed in vitro when exposed to DNMTi and regain their functional roles, thus pointing to the clinical potential epigenetic therapy may have in the treatment of infant leukemia.

Relapsed ALL is a highly aggressive disease marked predominantly by drug resistance (20). Efforts are currently being undertaken to identify the role of epigenetic mechanisms in driving relapse and chemoresistance (3). Genome-wide DNA methylation profiling performed on 33 matched relapse-diagnosis pairs demonstrated that the relapsed genome was distinctly more hypermethylated compared to matched samples at diagnosis (3). In this study, 1147 CpG sites corresponding to 905 genes were differentially hypermethylated at relapse. About a third of these genes exhibited concordant down-regulation of mRNA expression. Many of the known regulators of the Wnt pathway were hypermethylated and down regulated at relapse, including inhibitors of the β-catenin/TCF/LEF activity, as well as APC, WT1, cadherins (CDH1, CDH11), and SOX genes (SOX2, SOX8, SOX11, SOX21). Interestingly, PTPRO, a negative feedback inhibitor of the Wnt pathway that binds to Wnt and blocks its association with other receptors (21), was also hypermethylated and down regulated. This suggests that the Wnt pathway is over-activated at relapse and that aberrant DNA methylation may play a significant role in the activation of this pathway in relapsed ALL (3). Re-expression of these hypermethylated and down regulated genes was observed when leukemia cell lines were treated with decitabine. As well, enhanced chemosensitivity was observed when ALL cell lines and primary patient ALL samples were pretreated with decitabine followed by conventional cytotoxic chemotherapy (4).

In summary, DNA hypermethylation appears to play a significant role in the leukemogenesis of ALL and may be an important contributor toward relapse. As more studies interrogate the specific genes and or pathways influenced by hypermethylation in pediatric ALL, we will gain further insight toward strategies to therapeutically target these aberrant epigenetic changes and hopefully begin to make a greater impact in the treatment of this disease.

**HISTONE MODIFICATIONS**

Histones are small basic proteins involved in the spatial organization of DNA within the nucleus. The chromatin environment influences the “on–off” transcriptional states of a gene depending on the post-translational modifications of the histone proteins (22). Numerous covalent histone tail modifications, the most prominent being methylation and acetylation, can directly affect gene transcription (23). These modifications are highly specific for the particular amino acid position on the N-terminal tails of the histones. For example, H3K4me3, H3K9 acetylation, H3K14 acetylation, and H3K79me2 are associated with open chromatin structures and linked with transcriptional activation, while H3K9me3 and H3K27me3 are associated with closed chromatin, and hence transcriptional repression. These histone marks are regulated by the balance between competing enzymes such as the histone lysine methyltransferases (HKMTs) and histone demethylases (HKDMs), and the histone acetyltransferases (HATs) and histone deacetylases (HDACs) (24). Moreover, multiple histone modifications can be associated with critical regulatory elements of transcription such as enhancers, which can determine cell fate and differentiation (23, 25).

Mutations in epigenetic modifying genes are common in hematologic malignancies, including ALL (26–31). These mutations can result in a gain or loss of function of key genes known to regulate histone marks. Iaffo and colleagues, in pediatric ALL cell lines, have used global chromatin profiling, a tandem mass spectrometry strategy, to measure levels of histone modifications on bulk chromatin (29). In this work, a novel cluster of cell lines with a specific epigenetic signature was identified, characterized by increased dimethylation of histone H3 at lysine 36 (H3K36me2) and decreased unmodified H3K36. Approximately half of the cell lines in this cluster harbored the t(4;14) translocation, which is known to induce overexpression of NSD2 (24, 32, 33). NSD2 is a member of the HKMTs that catalyze the conversion of unmodified H3K36 to mono- and dimethylated forms (28). Upon targeted sequencing in an extensive patient sample set, NSD2 mutations were found to be enriched in ETV6–RUNX1 and TCF3–PBX1 sub-types of pediatric B-ALL, while no mutations were identified in 30 adult ALL samples. These were gain-of-function mutations and their overexpression led to a global increase in H3K36me2, with concomitant decrease in H3K27me3. Similar results were reported by others (34), showing these mutations affect expression of a number of genes involved in normal lymphoid development.

Accumulating evidence suggests that histone modification is an important aspect of MLL-fusion mediated transformation and leukemogenesis (35, 36). It has been shown that wild type MLL-SET domain is a methyltransferase, modifying histone H3 on lysine 4 (H3K4), and positively regulating gene expression of multiple Hox genes (37). In addition, MLL-mediated transcriptional regulation involves recruitment of HAT, such as CBP (38) and MOF (39). Furthermore, DOT1L, a histone methyltransferase that methylates lysine 79 on histone H3 (H3K79), has been associated with multiple MLL-fusion partners such as AF9, AF10, AF17, and ENL (40–42), and has emerged as an attractive therapeutic target (36). Several groups have used small molecule inhibitors to demonstrate the feasibility of pharmacological inhibition of DOT1L enzymatic activity in preclinical models of MLL-rearranged leukemia (43–45) and are now under clinical investigation in a phase I study for adults with advanced hematologic malignancies, including acute...
leukemia with rearrangement of the MLL gene (NCT01684150). One inhibitor in particular, EPZ-5676, has shown potent activity in its ability to selectively inhibit the DOT1L histone methyltransferase, resulting in cell death of acute leukemia cell lines harboring MLL translocations as well as complete tumor regression in a rat xenograft model of MLL-rearranged leukemia following continuous iv infusion of EPZ-5676 (45).

In order to identify novel mutations in relapsed ALL, Mullighan and colleagues performed targeted resequencing of 300 genes in 23 matched relapse-diagnosis B-ALL pairs (30). The authors identified novel mutations in CREBBP, a gene encoding the transcriptional coactivator CREB binding protein with HAT activity. The overall frequencies of these sequences and/or deletional mutations were 18.3% in relapse cases (30). However, particularly high incidences of somatic CREBBP alterations (63%) were found in the high hyperdiploidy relapse cases. Of note, the majority of these mutations occurred in the HAT domain (27). Although less common, mutations in other important epigenetic regulators were also seen such as NCoR1 (Nuclear corepressor complex), EP300 (a paralog of CREBBP), EZH2 (histone methyltransferase gene), and CTCF (zinc finger protein involved in histone modifications) (30). Additionally, transcriptome sequencing has identified relapse-specific mutations in CBX3 (encoding heterochromatin protein), PRMT2 (gene encoding protein arginine methyltransferase 2), and MIER3 (involved in chromatin binding); providing further evidence of aberrant epigenetic mechanisms that play a role at relapse (46).

Epigenetic alterations are not only restricted to B-ALL, but are a notable feature of T-ALL, particularly the aggressive subtype early T-cell precursor (ETP) ALL. Whole genome sequencing of 12 cases of ETP ALL identified mutations in genes encoding components of the polycomb repressor complex 2 (PRC2), including deletions and sequence mutations of EZH2, SUZ12, and EED (47). Loss of function mutations and deletions of EZH2 and SUZ12 genes have also been found in T-ALL, where authors implicate the tumor suppressor role of the PRC2 complex (48).

In addition to the discovery of somatic mutations in epigenetic machinery in ALL, mRNA expression of HDACs has been shown to be dysregulated. Higher mRNA expression of HDAC7 and HDAC9 in a study of 94 childhood ALL cases was shown to correlate with poor prognosis (49). Similarly, another group identified the correlation of HDAC4 overexpression with prednisone poor response, T-ALL phenotype, and a high initial WBC (50). Given the compelling evidence of HDAC’s involvement in tumor development and progression, inhibitors of HDACs have emerged as an attractive therapeutic option in hematologic malignancies (4, 51). Through a connectivity map search (52) for agents, the potential importance of these changes is highlighted by the promising activity of several other drugs from the same class that target epigenetic alterations (55).

MicroRNA ALTERATIONS

MicroRNAs are a class of small endogenous single stranded non-coding ribonucleic acids (RNA) composed of roughly 22 nucleotides that are primarily involved in post-transcriptional gene regulation. miRNAs play a critical regulatory role in targeting mRNAs for cleavage or translational repression, with greater than 1,000 miRNAs currently identified in the human genome (56). MicroRNA genes are preferentially localized to CpG islands, which leads to the plausible mechanism that they can be controlled through aberrant epigenetic regulation (e.g., hypermethylation, histone modification) (57).

Altered expression of miRNAs has been implicated in leukemogenesis and appears to have the ability to influence critical growth regulatory pathways in ALL (58–61). An example of the functional impact miRNA can have in B-cell ALL was reported with the restoration of miR-196b expression, which led to significant down-regulation of c-myc and its effector genes fli1TERT, Bcl-2, and AATF, suggesting a tumor suppressor function role for miR-196b (62). Some specific miRNAs that have been implicated in pediatric ALL include miRNA (miR) miR-34, miR-128, and miR-142, and miR-100 and miR-196b, both under expressed (59, 63). Schotte and colleagues investigated 397 miRNAs using qRT-PCR in 81 pediatric ALL cases in comparison to 17 normal CD34+ stem cell controls (65). Unique miRNA signatures were identified for various ALL sub-types including ETV6-RUNX1, MLL-rearranged, T-ALL, hyperdiploidy, and E2A-PBX1. Overall, expression of miR-143 and miR-140 were found to be 70- and 140-fold lower in the B-ALL samples compared to controls (pFDR = 0.0007 and pFDR = 0.001, respectively). Hyperdiploid samples showed a clustering of high expression of miR-98, miR-222, miR-223, and miR-511 and the ETV6-RUNX1 cases had a 5- to 1700-fold increase expression in miR-99a, miR-100, miR-125b, and miR-383 compared to controls (pFDR < 0.001). Together these findings lend support for epigenetic alterations involving miRNAs in the leukemogenesis of some of the more common variants of pediatric ALL.

Aberrant miRNA expression has been implicated in leukemia drug resistance and lower event-free survival (EFS). Schotte and colleagues identified a lower expression of miR-454 (1.9-fold lower) in leukemia blasts with L-asparaginase resistance (pFDR = 0.017) and patient samples resistant to vincristine and
daunorubicin were found to have over expression of miR-99a, miR-100, and miR-125b (14- to 25-fold) \( p_{\text{FDR}} \leq 0.002 \) and \( p_{\text{FDR}} < 0.05 \), respectively (65). In terms of EFS, six miRNAs (miR-33, -215, -369-3p, -496, -518d, and -599) were associated with worse survival (HR 1.3–1.52, 95% CI 1.01–2.04; 0.003 \( p \leq 0.046 \)) and another eight (miR-10a, -134, -214, -484, -572, -580, -624, and -627) with greater EFS (HR 0.59–0.82, 95% CI 0.41–0.99, 0.004 \( p \leq 0.045 \)) (65). The authors concluded that the miRNAs associated with a more favorable outcome likely had tumor suppressor activity through their signaling of apoptosis (miR-10a), inhibition of proliferation (miR-10a and miR-214), and oncogene SOX2 down-regulation (miR-134).

In a report of 18 matched-pair diagnosis and relapse \( n = 8 \) or diagnosis and remission \( n = 10 \) pediatric ALL samples, data was summarized for the most differentially expressed miRNAs (66). Down-regulation of miR-23a and miR-223 was observed at time of relapse compared to remission whereas miR130b, -181, and -708 were over expressed at relapse. Specifically, the expression of miR-708 was greater in relapse samples and lower in remission samples when compared to diagnosis whereas miR-223 was up-regulated in remission samples compared to diagnosis and confirmed with qRT-PCR. These two miRNAs at diagnosis along with miR-27a were shown to correlate significantly with 3-year relapse-free survival (45x) with miR-27a were shown to correlate significantly with 3-year relapse-free survival (45x) confirmed with qRT-PCR. These two miRNAs at diagnosis along with miR-27a were shown to correlate significantly with 3-year relapse-free survival (45x).

In summary, aberrant miRNA expression, particularly secondary to methylation, is a common finding in ALL. These data support that epigenetic modifications of specific miRNAs are associated with chemotherapy resistance and clinical outcomes. As these modifications can be secondary to DNA hypermethylation (65, 68–71), exposure to agents such as DNMTi could reverse the aberrant expression, normalize miRNA levels, and ultimately lead to improved clinical outcomes.

**CLINICAL TRIALS INVESTIGATING EPIGENETIC MODIFYING THERAPIES IN PEDIATRIC ALL**

The majority of clinical experience using epigenetic modifying agents in the treatment of acute leukemia has been in adults (72, 73). The Children's Oncology Group (COG) piloted a phase I study investigating decitabine (10 mg/m\(^2\)/day \times 5\) days/week \times 2\) weeks) in children with relapsed/refractory acute leukemia that closed prematurely due to low patient accrual (NCT00042796, unpublished). No maximum tolerated dose (MTD) was identified and 5/15 patients reported grade 3/4 cytopenias (anemia, thrombocytopenia, and leukopenia) that were possibly related to the study drug.

Similar to the DNMTi, HDACi (e.g., vorinostat, panobinostat) have been studied in the treatment of acute leukemia, primarily as single agents and almost exclusively in adults (74, 75). The COG completed a phase I study investigating vorinostat in combination with 13 cis-retinoic acid in children with refractory/recurrent solid tumors and vorinostat alone for patients with refractory leukemia (76). Six patients with refractory leukemia were enrolled with 2 DLTs reported at the solid tumor MTD (230 mg/m\(^2\)/day) including an elevated AST \( n = 1 \), hyperbilirubinemia \( n = 1 \), elevated GGT \( n = 1 \), and hypokalemia \( n = 1 \). As the solid tumor MTD for vorinostat did not appear tolerable for patients with hematologic malignancies, there was no further dose finding attempt in this study. Currently, there is a phase I study of panobinostat in children with refractory hematologic malignancies open through the therapeutic advances in childhood leukemia and lymphoma (TACL) Consortium (NCT01321346).

The first study incorporating a DNMTi and HDACi followed by chemotherapy for children and adults with relapsed/refractory ALL was recently completed (72). In this phase II trial, decitabine (15 mg/m\(^2\)/day) and vorinostat (230 mg/m\(^2\) divided BID) were given over four consecutive days prior to re-induction chemotherapy (vincristine, prednisone, PEG-asparaginase, doxorubicin) (NCT00882206) (72). Thirteen eligible patients enrolled with a median age of 16 (range, 3–54) years. There was a single toxic death occurring on study attributed to the chemotherapy regimen, which included a grade five hemorrhage/bleeding \( n = 1 \). A second patient experiencing grade five hypoxia/acute respiratory distress died on day 4 of study attributed to disease progression \( n = 1 \). There were an additional 14 grade 3/4 serious adverse events, which were at least possibly attributed to decitabine or vorinostat, the most common being fever with neutropenia \( n = 2 \) and infection (blood) with neutropenia \( n = 5 \). Results of the eight patients evaluable for response identified a CR rate of 50% \( (n = 4/8) \) (95% CI 15.7–84.3%) and an overall response rate \( (CR + PR) \) of 75% \( (n = 6/8) \) (95% CI 34.9–96.8%). As well, minimal residual disease (MRD) negativity by flow cytometry was observed in 4/8 patients (50%, CI: 15.7–84.3%). Five of the eight patients who completed the study proceeded to allogeneic hematopoietic cell transplantation (four in second CR and one in third CR). Three patients succumbed to transplant related deaths without evidence of leukemia while the remaining two patients remain alive with no evidence of disease. Based on the results of this study, a pediatric trial for relapse/refractory ALL combining decitabine and vorinostat with re-induction chemotherapy is currently open through the TACL Consortium (NCT01483690; R21CA161688-01).

**SUMMARY**

Underlying epigenetic alterations in pediatric ALL are common events, which appear to be more common at relapse than...
diagnosis. Thus children with relapse ALL may be an ideal population for clinical trials incorporating epigenetic modifying agents aimed at reversing these aberrant signatures. Whether such trials will lead to improved clinical outcomes has yet to be determined but early findings in studies incorporating these agents have been encouraging.

In conclusion, leukemogenesis of pediatric ALL is heavily influenced by epigenetics, particularly DNA hypermethylation, histone modification, and alterations in miRNA expression. Epigenetic modifying agents such as DNMTi and HDACi as well as newer strategies. Whether such trials aimed at reversing these aberrant signatures. Whether such trials will lead to improved clinical outcomes has yet to be determined but early findings in studies incorporating these agents have been encouraging.

REFERENCES

1. Garcia-Manero G, Yang H, Kuang SQ, O’Brien S, Thomas D, Kantarjian H. Epigenetics of acute lymphoblastic leukemia. Semin Hematol (2009) 46:24–32. doi:10.1053/j.seminhematol.2008.09.008
2. Sandoval I, Esteller M. Cancer epigenomics: beyond genomics. Curr Opin Genet Dev (2012) 22:50–5. doi:10.1016/j.gde.2012.02.008
3. Hogan LE, Meyer JA, Yang J, Wang J, Wong N, Yang W, et al. Integrated genomic signaling and its potential role as a receptor for Wnt. FEBS Lett (2010) 584:3923–8. doi:10.1016/j.febslet.2010.08.034
4. Scherf U, Ross DT, Waltham M, Lee J, Eisen MB, Botstein D, et al. Mapping and analysis of chromatin state dynamics in nine human cell types. Nature (2000) 409:45–51. doi:10.1038/35050506
5. Rada-Iglesias A, Bajpai R, Swift G, Brugmann SA, Wysocka J. A unique chromatin signature uncovers early developmental enhancers in humans. Nature (2011) 470:279–83. doi:10.1038/nature09692
6. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature (2013) 500:389–97. doi:10.1038/nature12317
7. Malgeri U, Baldini L, Perfetti V, Fabris S, Vignarelli MC, Colombo G, et al. Detection of FGFR3 and a novel FGFR3 fusion in myeloid malignancies. Blood (2013) 122:3616–27. doi:10.1182/blood-2013-08-518886
8. Malgeri U, Baldini L, Perfetti V, Fabris S, Vignarelli MC, Colombo G, et al. Detection of FGFR3 and a novel FGFR3 fusion in myeloid malignancies. Blood (2013) 122:3616–27. doi:10.1182/blood-2013-08-518886
9. Malgeri U, Baldini L, Perfetti V, Fabris S, Vignarelli MC, Colombo G, et al. Detection of FGFR3 and a novel FGFR3 fusion in myeloid malignancies. Blood (2013) 122:3616–27. doi:10.1182/blood-2013-08-518886
10. Malgeri U, Baldini L, Perfetti V, Fabris S, Vignarelli MC, Colombo G, et al. Detection of FGFR3 and a novel FGFR3 fusion in myeloid malignancies. Blood (2013) 122:3616–27. doi:10.1182/blood-2013-08-518886
11. Malgeri U, Baldini L, Perfetti V, Fabris S, Vignarelli MC, Colombo G, et al. Detection of FGFR3 and a novel FGFR3 fusion in myeloid malignancies. Blood (2013) 122:3616–27. doi:10.1182/blood-2013-08-518886
12. Malgeri U, Baldini L, Perfetti V, Fabris S, Vignarelli MC, Colombo G, et al. Detection of FGFR3 and a novel FGFR3 fusion in myeloid malignancies. Blood (2013) 122:3616–27. doi:10.1182/blood-2013-08-518886
13. Malgeri U, Baldini L, Perfetti V, Fabris S, Vignarelli MC, Colombo G, et al. Detection of FGFR3 and a novel FGFR3 fusion in myeloid malignancies. Blood (2013) 122:3616–27. doi:10.1182/blood-2013-08-518886
14. Malgeri U, Baldini L, Perfetti V, Fabris S, Vignarelli MC, Colombo G, et al. Detection of FGFR3 and a novel FGFR3 fusion in myeloid malignancies. Blood (2013) 122:3616–27. doi:10.1182/blood-2013-08-518886
15. Malgeri U, Baldini L, Perfetti V, Fabris S, Vignarelli MC, Colombo G, et al. Detection of FGFR3 and a novel FGFR3 fusion in myeloid malignancies. Blood (2013) 122:3616–27. doi:10.1182/blood-2013-08-518886
16. Malgeri U, Baldini L, Perfetti V, Fabris S, Vignarelli MC, Colombo G, et al. Detection of FGFR3 and a novel FGFR3 fusion in myeloid malignancies. Blood (2013) 122:3616–27. doi:10.1182/blood-2013-08-518886
35. Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU, et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell (2008) 14:355–68. doi:10.1016/j.ccc.2008.10.001
36. Bernt KM, Armstrong SA. Targeting epigenetic programs in MLL-rearranged leukemias. Hematology Am Soc Hematol Educ Program (2011) 2011:354–60. doi:10.1182/ash.2011.1.354
37. Melne TA, Briggs SD, Brock HW, Martin ME, Gibbs D, Allis CD, et al. SET domain methyltransferase activity to Hox gene promoters. Mol Cell (2002) 10:1107–17. doi:10.1016/S1097-2765(02)00741-4
38. Ernst P, Wang J, Huang M, Goodman RH, Korsmeyer SJ, MLL and CREB bind cooperatively to the nuclear coactivator CREBBP-binding protein. Mol Cell Biol (2001) 21:2249–58. doi:10.1128/MCB.21.7.2249-2258.2001
39. Duy O, Milne TA, Tackett AJ, Smith ER, Fukuda A, Wysocka J, et al. Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF. Cell (2005) 121:873–85. doi:10.1016/j.cell.2005.04.031
40. Okada Y, Feng Q, Lin Y, Jiang Q, Li Y, Coffield VM, et al. hDOT1L links histone methylation to leukemogenesis. Cell (2005) 121:167–78. doi:10.1016/j.cell.2005.05.021
41. Mueller D, Bach C, Zeisig D, Garcia-Cuellar M-P, Monroe S, Sreekumar A, et al. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood (2007) 110:4445–54. doi:10.1182/blood-2007-05-090514
42. Zhang W, Xia X, Reisenauer MR, Hemenway CS, Kone BC. Dot1a-AF9 complex mediates histone H3 Lys-79 hypermethylation and repression of ENaC in an aldosterone-sensitive manner. J Biol Chem (2006) 281:18059–68. doi:10.1074/jbc.M601903200
43. Daigle SR, Olhava EI, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell (2011) 20:53–65. doi:10.1016/j.ccr.2011.04.011
44. Chen L, Deshpande AJ, Banka D, Bernt KM, Dias S, Buske C, et al. Abrogation of activation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. J Biol Chem (2011) 286:2249–58. doi:10.1074/jbc.M110.110725
45. Zhang H, Luo XQ, Zhang P, Huang LB, Zheng YS, Wu J, et al. MicroRNA patterns with prognosis and survival in childhood acute lymphoblastic leukemia. Oncol Rep (2012) 28:97–106. doi:10.3892/or.2011.1435.9
46. Schotte D, Chau JC, Sylvester G, Liu Q, Chen G, van der Velden VH, et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Pediatr Hematol Oncol (2009) 26:1–10. doi:10.1088/08880010/29/12/S338
47. Schotte D, Schotte D, De Menezes RX, Akbari Moqadam F, Khankahdani LM, Lange-Turenneht E, Chen G, et al. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci USA (2007) 104:19971–7. doi:10.1073/pnas.0709313104
48. Daigle SR, Olhava EI, Therkelsen CA, Zane J, Mendoza LM, Boro A, et al. miRNA expression profiles in chronic lymphocytic and acute lymphoblastic leukemia. Blood (2011) 118:3641–50. doi:10.1182/blood-2011-01-333483
49. Moreno DA, Scrideli CA, Tonedi LG, Narendran A. MicroRNA genes in acute leukemia. Cancer Cell (2012) 26:97–106. doi:10.1016/j.ccr.2011.10.005
50. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. Epigenetics (2011) 6:119–28. doi:10.4166/epi.25799
51. Fiaschetti G, Abela L, Nonoguchi N, Dubuc AM, Remke M, Boro A, et al. Epigenetic silencing of miRNA-9 is associated with HES1 oncogenic activation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia (2013) 27:813–22. doi:10.1038/leu.2012.327
52. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol (2009) 27:5459–68. doi:10.1200/JCO.2009.22.1291
53. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 313:1929–35. doi:10.1126/science.1132939
54. Philippa D, Kang H, Moskowitz NP, Min DI, Lee H, Potter JW, et al. Biological pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children’s Oncology Group study. Blood (2006) 108:711–7. doi:10.1182/blood-2006-02-002824
55. Bachmann PS, Piazza RG, James ME, Wong NC, Davies C, Mogavero A, et al. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood (2010) 116:3013–22. doi:10.1182/blood-2010-05-284968
56. Jones PA, Baylin SB. The epigenomics of cancer. Cell (2007) 128:683–92. doi:10.1016/j.cell.2007.01.029
57. de Oliveira JC, Brascose MS, Scrideli CA, Tone LG, Narendran A. MicroRNA expression and activity in pediatric acute lymphoblastic leukemia (ALL). Pediatr Blood Cancer (2012) 59:599–604. doi:10.1002/pbc.23417
58. Weber B, Stremmann C, Bruckerker B, Lyko F. Methylation of human microRNA genes in normal and neoplastic cells. Cell Cycle (2007) 6:1001–5. doi:10.1080/15384100691328420
59. Burke and Bhatla Epigenetic modifications in ALL
hyper-CVAD, in relapsed or refractory acute lymphocytic leukemia (ALL). *ASH Annual Meeting Abstracts* (2007) 110:2826.

74. Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. *Clin Cancer Res* (2006) 12:4628–35. doi:10.1158/1078-0432.CCR-06-0511

75. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, et al. Phase I study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. *Blood* (2008) 111:1060–6. doi:10.1182/blood-2007-06-098061

76. Fouladi M, Park JR, Stewart CF, Gilbertson RJ, Schuiquevich P, Sun J, et al. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. *J Clin Oncol* (2010) 28:3623–9. doi:10.1200/JCO.2009.25.9119

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 30 January 2014; accepted: 29 April 2014; published online: 14 May 2014.

Citation: Burke MJ and Bhatla T (2014) Epigenetic modifications in pediatric acute lymphoblastic leukemia. *Front. Pediatr.* 2:42. doi: 10.3389/fped.2014.00042

This article was submitted to Pediatric Oncology, a section of the journal *Frontiers in Pediatrics.*

Copyright © 2014 Burke and Bhatla. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.